Heparin blocks transfer of extracellular vesicles between donor and recipient cells

[1]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[2]  Ylva Ivarsson,et al.  Syndecan–syntenin–ALIX regulates the biogenesis of exosomes , 2012, Nature Cell Biology.

[3]  X. Breakefield,et al.  Microvesicle-associated AAV vector as a novel gene delivery system. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[5]  S. Pomeroy,et al.  Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. , 2011, Nature communications.

[6]  C. Spek,et al.  Experimental and clinical effects of anticoagulants on cancer progression. , 2010, Thrombosis research.

[7]  T. D. de Gruijl,et al.  Functional delivery of viral miRNAs via exosomes , 2010, Proceedings of the National Academy of Sciences.

[8]  J. Rak,et al.  Microvesicles: Messengers and mediators of tumor progression , 2009, Cell cycle.

[9]  A. Iglič,et al.  Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin. , 2009, Blood cells, molecules & diseases.

[10]  A. Stemmer-Rachamimov,et al.  Preventing growth of brain tumors by creating a zone of resistance. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[12]  Aled Clayton,et al.  Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. , 2007, Cancer research.

[13]  Mohamed Hatmi,et al.  Clinical Studies with Anticoagulants to Improve Survival in Cancer Patients , 2007, Pathophysiology of Haemostasis and Thrombosis.

[14]  P. Reitsma,et al.  Mechanisms of heparin induced anti-cancer activity in experimental cancer models. , 2007, Critical reviews in oncology/hematology.

[15]  J. Lykke.  [Heparin and cancer]. , 2006, Ugeskrift for laeger.

[16]  T. Whiteside,et al.  Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles , 2006, Immunologic research.

[17]  M. Sumida,et al.  Isolation and identification of histone H3 protein enriched in microvesicles secreted from cultured sebocytes. , 2005, Endocrinology.

[18]  L. Zitvogel,et al.  The potential of exosomes in immunotherapy , 2005, Expert opinion on biological therapy.

[19]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[20]  David R. Nadeau,et al.  Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[22]  L. Zacharski,et al.  The Use of Heparin for Treating Human Malignancies , 1999, Pathophysiology of Haemostasis and Thrombosis.

[23]  Susanne M. Smorenburg,et al.  The Effects of Unfractionated Heparin on Survival in Patients with Malignancy – A Systematic Review , 1999, Thrombosis and Haemostasis.

[24]  M. Levine,et al.  Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread , 1999, Thrombosis and Haemostasis.

[25]  M. Porcionatto,et al.  Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates? , 1999, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[26]  H. Engelberg.  Actions of heparin that may affect the malignant process , 1999, Cancer.

[27]  M. Raderer,et al.  Inhibition of metastases by anticoagulants. , 1999, Journal of the National Cancer Institute.

[28]  H. Rauschecker,et al.  Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. , 1997, European journal of cancer.

[29]  M. Joannidis,et al.  Management of venous thromboembolism. , 1997, The New England journal of medicine.

[30]  E. Lemarié,et al.  Subcutaneous heparin treatment increases survival in small cell lung cancer , 1994, Cancer.